Table 4 Clinical trials based on MSCs
Target | Drug or intervation | Combination | Condition | Phase | Status | Trial number |
|---|---|---|---|---|---|---|
IDO | Navoximod | No | Solid Tumor | I | Completed | NCT02048709 |
| Â | Navoximod | Atezolizumab | Locally Advanced or Metastatic Solid Tumors | I | Completed | NCT02471846 |
Engineered MSC | BM-MSC-INFβ | No | Ovarian cancer | I | Completed | NCT02530047 |
| Â | MSC-TRAIL | No | Adenocarcinoma of lung | I/II | Recruiting | NCT03298763 |
| Â | GX-051 | No | Head and neck cancer | I | Unknown | NCT02079324 |
| Â | CELYVIR | No | Metastatic and refractory tumors | I/II | Completed | NCT01844661 |
| Â | AdMSC-MV-NIS | No | Ovarian, primary peritoneal or fallopian tube cancer | I/II | Recruiting | NCT02068794 |
| Â | AloCELYVIR | No | Diffuse Intrinsic Pontine Glioma | I/II | Recruiting | NCT04758533 |
MSC-derived exosome | iExosomes | No | Metastatic pancreas cancer | I | Recruiting | NCT03608631 |
Tissue-derived MSC | HB-adMSCs | No | Pancreatic cancer | I | Unknown | NCT04087889 |
| Â | EB-CMF | No | Mandible tumor | I/II | Recruiting | NCT03678467 |
| Â | Cord blood MSCs | NeuroRegen Scaffoldâ„¢ | Rectal cancer | I/II | Recruiting | NCT02648386 |
| Â | MSCs | Hematopoietic stem cells | Leukemia, lymphoma, and myeloma | II | Terminated | NCT01045382 |
|  | IFNγ-primed bone marrow MSCs | No | Acute leukemia | I | Recruiting | NCT04328714 |